Holen Sie sich die Stockscreener-App
2.35
1.26%
-0.03
Handel nachbörslich:
2.40
0.05
+2.13%
Schlusskurs vom Vortag:
$2.38
Offen:
$2.38
24-Stunden-Volumen:
368.49K
Relative Volume:
0.09
Marktkapitalisierung:
$131.39M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
235.00
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
-5.24%
1M Leistung:
-18.40%
6M Leistung:
+170.83%
1J Leistung:
+70.29%
1-Tages-Spanne:
$2.35
$2.41
1-Wochen-Bereich:
$2.30
$2.531
52-Wochen-Spanne:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.35 | 134.74M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
What analysts say about Spero Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional
What institutions are buying Spero Therapeutics Inc. stock nowBreakneck growth rates - jammulinksnews.com
What drives Spero Therapeutics Inc. stock priceTremendous portfolio expansion - PrintWeekIndia
What risks could impact Spero Therapeutics Inc. stock performanceOutstanding stock performance - jammulinksnews.com
Why Spero Therapeutics Inc. stock is on top investor watchlistsOutstanding capital appreciation - jammulinksnews.com
Spero Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - jammulinksnews.com
Is Spero Therapeutics Inc. a good long term investmentFree Bull & Bear Market Updates - Autocar Professional
Will Spero Therapeutics Inc. stock benefit from AI tech trendsTrend Based Entry Alerts - Newser
When is the best time to buy Spero Therapeutics Inc. stockFree Real-Time Trading Opportunities - Newser
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price - simplywall.st
What makes Spero Therapeutics Inc. stock price move sharplyMarket Timing Advice - Newser
Why Spero Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
How Spero Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average – What’s Next? - Defense World
While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership - Yahoo
Is Spero Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha
Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN
Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey
Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa
Complicated Urinary Tract Infection Oral Antibiotic Approaches Approval - Vax-Before-Travel
Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):